Weight-for-age distributions among children with HIV on antiretroviral therapy in the International epidemiology Databases to Evaluate AIDS (IeDEA) multiregional consortium by Jesson, Julie et al.
Jesson et al. BMC Res Notes          (2020) 13:249  
https://doi.org/10.1186/s13104-020-05081-7
RESEARCH NOTE
Weight-for-age distributions among children 
with HIV on antiretroviral therapy 
in the International epidemiology Databases 
to Evaluate AIDS (IeDEA) multiregional 
consortium
Julie Jesson1,13*† , Sophie Desmonde1†, Constantin T. Yiannoutsos2, Gabriela Patten3, Karen Malateste4,5, 
Stephany N. Duda6, Nagalingeswaran Kumarasamy7, Marcel Yotebieng8, Mary‑Ann Davies3, Beverly Musick9, 
Valeriane Leroy1 and Andrea Ciaranello10,11,12 on behalf of IeDEA
Abstract 
Objective: Pediatric antiretroviral therapy (ART) for children with HIV (CHIV) must be dosed appropriately for 
children’s changing weights as they grow. To inform accurate estimates of ART formulations and doses needed, we 
described weight‑for‑age distributions among CHIV on ART in the IeDEA global pediatric collaboration between 
2004 and 2016, using data from six regions (East, West, Central, and Southern Africa, Asia–Pacific, and Central/South 
America and the Caribbean).
Results: Overall, 59,862 children contributed to the analysis. Age and weight data were available from 530,080 clini‑
cal encounters for girls and 537,894 for boys. For each one‑year age stratum from 0 to 15 years, we calculated the 
proportion of children in each of the weight bands designated by the World Health Organization as relevant to pedi‑
atric ART formulations: 0 to  < 3 kg, 3 to  < 6 kg, 6 to  < 10 kg, 10 to  < 14 kg, 14 to  < 20 kg, 20 to  < 25 kg, 25 to  < 30 kg, 
30 to  < 35 kg, 35 to  < 40 kg, 40 to  < 45 kg, 45 to  < 50 kg, 50 to  < 55 kg, 55 to  < 60 kg, and ≥ 60 kg. Data are reported 
for the entire cohort, as well as stratified by sex and IeDEA region, calendar year of ART use, and duration on ART at 
time of assessment (< 12 or ≥ 12 months), provided in data tables. These data are critical to improve the accuracy of 
forecasting and procurement of pediatric ART formulations as the pediatric HIV epidemic and pediatric HIV treatment 
strategies evolve.
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Introduction
Children with HIV (CHIV) require appropriate dos-
ing of pediatric antiretroviral therapy (ART) to prevent 
HIV-related morbidity and mortality. HIV programs at 
national and international levels procure annual quan-
tities of pediatric ART based on forecasts of the num-
ber of children likely to require each drug formulation 
and dose; dosing is weight-based in children < 15  years 
of age. Accurate forecasting of antiretroviral needs is 
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particularly important, because the pediatric antiretro-
viral market is small. Procurement volume has a large 
impact on market prices and failure to procure sufficient 
quantities of antiretroviral medications (ARVs) leads 
to gaps in treatment access in low-income and middle-
income countries [1]. While validated estimates exist of 
the numbers of children at each age likely to need ART 
[2], additional information about the weight distribu-
tion for CHIV by age are needed to permit accurate fore-
casts of the medication quantities that will be required. 
To date, ART forecasts rely on WHO and CDC growth 
curves for all children in the general population [3–5]. 
However, children and adolescents living with HIV are 
often malnourished at the time of initiating ART and 
their catch-up growth can be delayed even after initiating 
ART [6–9]. Because of these key differences for CHIV, 
growth curves derived from the general population likely 
overestimate weight-for-age among CHIV and therefore 
may lead to inaccurate estimates of the number of formu-
lations and doses of pediatric ART that will be required 
globally [10]. Accurate data about volume trends in 
weight-for-age evolution among ART-treated CHIV are 
therefore needed to appropriately inform ART forecast-
ing efforts [11].
This study reports a secondary analysis of data from a 
parent study conducted within the global International 
epidemiology Databases to Evaluate AIDS (IeDEA) pedi-
atric research consortium (https ://www.iedea .org/). The 
parent study sought to analyze age- and CD4-stratified 
risks of opportunistic infections and mortality for CHIV 
before and after ART initiation in six global IeDEA 
regions [12]. Using the database assembled for the parent 
study, we conducted a separate analysis, reported here, 
to evaluate the weight-for-age distributions in CHIV 
on ART in the IeDEA consortium in order to support 
accurate forecasting and procurement of pediatric ART 
formulations.
Main text
Methods
We analyzed individual patient data from the six regional 
pediatric cohorts within IeDEA: Asia–Pacific, West 
Africa, East Africa, Central Africa, Southern Africa, and 
the Caribbean, Central, and South America network 
(CCASAnet) [13]. Using eligibility criteria from the par-
ent study [12], all patients were included if they enrolled 
into care at age < 24 years, were followed-up at any of the 
participating IeDEA sites between 2004 and 2016, had a 
confirmed HIV diagnosis, were ART-naïve at enrolment, 
and had at least one CD4 count or percent measure-
ment during follow-up. In the current analysis, we lim-
ited the dataset to children aged < 15 years, because older 
youth primarily use adult ARV formulations and doses. 
Although clinic protocols vary across the IeDEA con-
sortium, CHIV are usually seen at least every 3 months 
while on ART. The data were generated during rou-
tine care encounters and included region, country, site, 
patient demographics (sex, date of birth, date of HIV 
diagnosis if available, and date of enrolment in care), 
laboratory values (CD4 count, CD4 percent), date of ART 
initiation, initial ART regimen, date of death, date of last 
clinical contact, and date of transfer out. Each partici-
pating IeDEA region obtained local institutional review 
board approval to participate. Written informed consent 
requirements were deferred to the local institutional 
review boards. The analysis only used de-identified data 
that had been collected as part of routine clinical care.
For the current study, we used data on weight at each 
visit as recorded in the medical record. For each one-year 
age stratum from 0 to 15 years, we calculated the num-
ber of children in each of the weight bands designated by 
the World Health Organization (WHO) to be relevant 
to pediatric ART formulations: 0 to  < 3  kg, 3 to  < 6  kg, 
6 to  < 10 kg, 10 to  < 14 kg, 14 to  < 20 kg, 20 to  < 25 kg, 
25 to  < 30 kg, 30 to  < 35 kg, 35 to  < 40 kg, 40 to  < 45 kg, 
45 to  < 50 kg, 50 to  < 55 kg, 55 to  < 60 kg, and ≥ 60 kg. 
We derived these numbers, and resulting proportions, 
for the entire cohort of CHIV, total and stratified by sex; 
we additionally derived numbers and proportions strati-
fied by sex and IeDEA region, calendar year of enrol-
ment (before versus beyond January 1, 2013), and time 
on ART (< 12  months or ≥ 12  months). Children for 
whom sex was unknown were excluded from the analy-
sis. Age at each visit was calculated based on the date of 
birth recorded in the database. A single child contrib-
uted multiple weight measurements over time and we 
deleted outlying measurements based on the following 
criteria: (1) weight-for-age z-scores (WAZ) > 3 for infants 
aged < 1  year, WAZ < − 8 for children aged < 5  years, 
WAZ < − 6 for children aged 5–10 years, and WAZ > 5 for 
all ages; (2) two values measured within the same month 
with a difference greater than 5 kg if age < 5 years, 8 kg if 
age 5 to  < 10 years, and 10 kg if age 10–15 years.
Results
Overall, 59,862 children and adolescents with HIV con-
tributed to the analysis, of whom 50.7% were females. 
Demographic information is shown in Table 1. Age and 
weight data were available from 530,080 clinical encoun-
ters for girls and 537,894 clinical encounters for boys. 
Sex-stratified results for all CHIV in the study are shown 
in Table  2. Additional tables are included in Additional 
file 1: 
 1. Overall population (combined).
 2. By sex (Table 2).
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 3. By IeDEA region, boys.
 4. By IeDEA region, girls.
 5. By ART duration and sex.
 6. By year of visit and sex.
 7. By IeDEA region, ART duration, boys.
 8. By IeDEA region, ART duration, girls.
 9. By IeDEA region, ART duration, < 2013, Boys.
 10. By IeDEA region, ART duration, < 2013, Girls.
 11. By IeDEA region, ART duration, ≥ 2013, Boys.
 12. By IeDEA region, ART duration, ≥2013, Girls. 
Limitations
This study is subject to a number of limitations. Several 
characteristics of patients participating in the IeDEA 
cohort may lead to overestimation of the weight-for-age 
distribution of children receiving ART and thus may 
overestimate the amount of active pharmaceutical ingre-
dient required per child. The first is survivorship bias, 
because CHIV who survived to initiate ART at IeDEA 
sites from 2004 to 2016 may have been healthier (and 
perhaps with higher weights for age) than those who 
did not. Children in this cohort do not represent a com-
plete cohort of CHIV followed from birth, and there was 
likely a high risk of death in children before the age of 
2 years who therefore never entered the study. Similarly, 
a high proportion of CHIV were lost to follow-up during 
the study period, possibly leaving a healthier cohort to 
remain in care and with evaluable weights and ages. Nev-
ertheless, these data likely accurately reflect weight-for-
age among children who remained on treatment and for 
whom ARV procurement estimates currently apply, even 
if they may overestimate weight for the full population of 
CHIV in need of ART. On the other hand, approximately 
two-thirds of IeDEA sites are located at university hos-
pitals in capital cities, where the standard of care may be 
different than in rural areas; if more intensive HIV care is 
provided, children at IeDEA sites may be healthier than 
at more rural sites in the same regions [13]. We also note 
a potential selection bias induced by the parent study, 
which only included children with available CD4 counts 
during follow-up, thus excluding the sicker children who 
may have initiated ART immediately, without their car-
egivers waiting for CD4 counts. This may also be possibly 
overestimating weights for ART-treated CHIV.
A second set of limitations may counteract these trends 
and may underestimate the quantities of active pharma-
ceutical ingredients needed. For example, before ART 
was recommended for all CHIV in 2013, it was offered 
only to the sickest children, potentially introducing an 
indication bias. This selection bias may particularly apply 
to older children in the IeDEA cohort, as access to early 
ART has improved over time for children, so adolescents 
aged 10–15  years in the future may be in better health 
than those observed in the IeDEA cohort over the study 
period reported in this study [14].
Despite these limitations, this dataset is, to our knowl-
edge, the only available source of data about weight-for-
age distributions among CHIV treated with ART built 
on the strength of a large cohort size and broad geo-
graphic coverage. Consequently, the resulting estimates 
and those, more generally, derived from observational 
cohorts conducted in real-world settings, offer a valuable 
opportunity to derive data-driven weight-for-age distri-
butions among CHIV [15, 16].
These data were originally pooled to support ade-
quate forecasting and procurement of pediatric ART 
formulations. Nevertheless, beyond this purpose, data 
about weight in children may also be helpful to create 
a secondary-hand framework for observing changes 
overtime regarding growth on ART, during childhood 
and adolescence as this has been done in the past [7, 
11]. Especially, these data will be useful in refining pro-
jections of the number of CHIV who may need specific 
ARV formulations and doses allowing HIV care and 
treatment programs to procure sufficient quantities of 
medications for CHIV, avoiding both medication stock 
Table 1 Characteristics of  the  59,862 children in  IeDEA 
at baseline
CCASAnet the Caribbean, Central and South American Network, ART 
antiretroviral therapy, IQR interquartile range
Characteristic
Region, n (%)
 Asia–Pacific 4004 (6.7)
 CCASAnet 1502 (2.5)
 Central Africa 2050 (3.4)
 East Africa 11,068 (18.5)
 Southern Africa 36,679 (61.3)
 West Africa 4559 (7.6)
Age, median (IQR), years 6.1 (2.5–9.9)
Female, n (%) 30,343 (50.7)
Year at ART initiation
 Year, n (%)
  < 2004 1729 (2.9)
  2004–2007 17,821 (29.8)
  2008–2012 31,272 (52.2)
  2013–2014 7493 (12.5)
  2015–2016 1547 (2.6)
 Number of observations by year of visit
  < 2004 16,505 (1.5)
  2004–2007 178,985 (16.8)
  2008–2012 610,078 (57.1)
  2013–2014 207,899 (19.5)
  2015–2016 54,507 (5.1)
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outs and medication wastage, furthering the critical 
goal of improving access to ART for CHIV globally [1].
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tium ‑ complete tables.
Abbreviations
CHIV: Children with HIV; ART : Antiretroviral Therapy; ARV: Antiretroviral medica‑
tion; IeDEA: International epidemiology Databases to Evaluate AIDS; WHO: 
World Health Organization.
Acknowledgements
We gratefully acknowledge all of the children and their families followed 
up in the participating pediatric centers. We also thank the staff from all 
participating pediatric centers. We warmly thank all the investigators and 
pediatric coordinators from the IeDEA regions contributing to the project: 
Asia–Pacific (Annette Sohn), CCASAnet–Latin America (Jorge Pinto and Cath‑
erine McGowan), Central Africa (Marcel Yotebieng and Andrew Edmonds), 
East Africa (Kara Wools‑Kaloustian), Southern Africa (Mary‑Ann Davies), West 
Africa (François Dabis and Valériane Leroy), the IeDEA Pediatric Working Group 
(Rachel Vreeman, Chair).
Authors’ contributions
JJ, SDe, VL, CY, MAD and ALC designed the study and prepared concept sheets 
for submission to and approval by the IeDEA network. KM, BM, GP, NK, SDu 
and MY provided the data. JJ analyzed the data. SDe, VL, and ALC provided 
critical feedback on the analysis and interpretation. JJ, SDe, VL and AC drafted 
the manuscript. JJ and SDe contributed equally to this work. All authors read 
and approved the final manuscript.
Funding
This work was supported by the IeDEA Pediatric Methods and Modeling 
Group (IPM2) through a supplement to the IeDEA regional grants by the 
National Institute Of Child Health & Human Development (NICHD). Research 
reported in this publication was supported by the US National Institutes of 
Health. Asia–Pacific: The TREAT Asia Pediatric HIV Observational Database 
is an initiative of TREAT Asia, a program of amfAR, The Foundation for AIDS 
Research, with support from the US National Institutes of Health’s National 
Institute of Allergy and Infectious Diseases (NIAID), the Eunice Kennedy Shriver 
NICHD, National Cancer Institute (NCI), National Institute of Mental Health 
(NIMH), National Institute on Drug Abuse (NIDA), the National Heart, Lung, and 
Blood Institute (NHLBI), the National Institute on Alcohol Abuse and Alcohol‑
ism (NIAAA), the National Institute of Diabetes and Digestive and Kidney 
Diseases (NIDDK), and the Fogarty International Center as part of the Interna‑
tional Epidemiology Databases to Evaluate AIDS (IeDEA; U01AI069907). Carib‑
bean, Central and South America network for HIV epidemiology (CCASAnet) 
is a member cohort of IeDEA (U01AI069923), with support from NIAID, NICHD, 
NCI, NIMH, NHLBI, NIAAA, and NIDDK). Central Africa research reported in this 
publication was supported by the NIAID of the National Institutes of Health 
under Award Number U01AI096299. East African Research reported in this 
publication was supported by the Eunice Kennedy Shriver NICHD, NIDA, NCI, 
and NIMH, in accordance with the regulatory requirements of the National 
Institutes of Health under Award Number U01AI069911, East Africa IeDEA 
Consortium. Southern African research reported in this publication was sup‑
ported by the NIAID of the National Institutes of Health under Award Number 
U01AI069924. West African Research reported in this publication was sup‑
ported by the US National Institutes of Health (NIAID, NICHD, NCI and NIMH) 
under Award Number U01AI069919. Additional support for ALC and SDe was 
provided by the Eunice Kennedy Shriver NICHD; R01 HD079214. The funders 
had no role in study design, data collection and analysis, decision to publish, 
or preparation of the manuscript. The content of this publication is solely the 
responsibility of the authors and does not necessarily represent the official 
views of any of the governments or institutions mentioned above.
 Availability of data and materials
The datasets generated during and/or analyzed during the current study are 
not publicly available due to legal and ethics restrictions. The principles of col‑
laboration of the IeDEA cohort consortium and the regulatory requirements of 
the individual member site and country institutional review boards require the 
submission and approval of a project concept sheet by the IeDEA Executive 
Committee, and the principal investigators and local site investigators from 
participating regions. IeDEA promotes the signing of a Data Use Agreement 
before HIV clinical data can be released. Individuals interested in obtaining 
access to data may contact IeDEA for additional information at https ://www.
iedea .org/home/who‑we‑are/. The project concept sheet template and other 
research‑related resources are available at https ://www.iedea .org/resou rces/.
Ethics approval and consent to participate
The IeDEA data analyzed in this manuscript were collected from over 300 sites 
in 35 countries. Each of the local sites and regional cohort data and coordinat‑
ing centers has their own IRBs under which they are authorized to collect 
and analyze research data. These IRBs are all registered with the US Officer of 
Human Research Protections of the US Department of Health and Human 
Services, and local approval by these IRBs is required prior to receiving IeDEA 
funding. This work was also approved by the Partners Healthcare IRB (Boston, 
MA).
Consent for publication
Not applicable (no individual patient data are reported).
Competing interests
The authors declare that they have no competing interests.
Author details
1 Inserm U1027, Université Paul Sabatier Toulouse 3, Toulouse, France. 2 Indiana 
University, Fairbanks School of Public Health, Indianapolis, IN, USA. 3 School 
of Public Health and Family Medicine, Faculty of Health Sciences, University 
of Cape Town, Cape Town, South Africa. 4 Inserm U1219, Bordeaux, France. 
5 Bordeaux Population Health Center, Université de Bordeaux, Bordeaux, 
France. 6 Vanderbilt University Medical Center, Nashville, TN, USA. 7 Chennai 
Antiviral Research and Treatment Clinical Research Site (CART CRS), VHS‑
Infectious Diseases Medical Centre, VHS, Chennai, India. 8 Division of Epidemi‑
ology, The Ohio State University, College of Public Health, Columbus, OH, USA. 
9 Indiana University School of Medicine, Indianapolis, IN, USA. 10 The Medical 
Practice Evaluation Center, Boston, MA, USA. 11 The Division of General Internal 
Medicine, Department of Medicine, Harvard Medical School, Boston, MA, USA. 
12 Massachusetts General Hospital, Boston, MA, USA. 13 Inserm, UMR 1027 ‑ 
Epidémiologie et analyses en santé publique: risques, maladies chroniques et 
handicaps ‑ Université Paul Sabatier Toulouse 3, Equipe 2: Axe santé de l’enfant 
et de l’adolescent en Afrique, 37 Allées Jules Guesde, 31073 Toulouse Cedex 7, 
France, Toulouse Cedex 7, France. 
Received: 3 December 2019   Accepted: 3 May 2020
References
 1. Lee JSF, Sagaon Teyssier L, Dongmo Nguimfack B, Collins IJ, Lallemant M, 
Perriens J, et al. An analysis of volumes, prices and pricing trends of the 
pediatric antiretroviral market in developing countries from 2004 to 2012. 
BMC Pediatr. 2016;16:41.
 2. World Health Organisation. UNAIDS DATA 2019 2019. https ://www.unaid 
s.org/sites /defau lt/files /media _asset /2019‑UNAID S‑data_en.pdf.
 3. Doherty K, Essajee S, Penazzato M, Holmes C, Resch S, Ciaranello A. Esti‑
mating age‑based antiretroviral therapy costs for HIV‑infected children 
in resource‑limited settings based on World Health Organization weight‑
based dosing recommendations. BMC Health Serv Res. 2014;14:201.
 4. World Health Organisation Multicentre Growth Reference Study Group. 
WHO Child Growth Standards: Length/Height‑for‑age, Weight‑for‑
age,Weight‑for‑Length, Weight‑for‑Height and Body Mass Index‑for‑age: 
Page 6 of 6Jesson et al. BMC Res Notes          (2020) 13:249 
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
Methods and Development. 2006. http://www.who.int/child growt h/
stand ards/techn ical_repor t/en/index .html.
 5. Center for Disease Control and Prevention (CDC). Data Table of Weight‑
for‑age Charts 2001. http://www.cdc.gov/growt hchar ts/html_chart s/
wtage .htm.
 6. McGrath CJ, Diener L, Richardson BA, Peacock‑Chambers E, John‑
Stewart GC. Growth reconstitution following antiretroviral therapy and 
nutritional supplementation: systematic review and meta‑analysis. AIDS. 
2015;29(15):2009–23.
 7. Jesson J, Koumakpai S, Diagne NR, Amorissani‑Folquet M, Koueta F, Aka A, 
et al. Effect of age at antiretroviral therapy initiation on catch‑up growth 
within the first 24 months among HIV‑infected children in the IeDEA 
West African Pediatric Cohort. Pediatr Infect Dis J. 2015;34(7):e159–68.
 8. Gsponer T, Weigel R, Davies M‑A, Bolton C, Moultrie H, Vaz P, et al. Vari‑
ability of growth in children starting antiretroviral treatment in southern 
Africa. Pediatrics. 2012;130(4):e966–77.
 9. Yotebieng M, Van Rie A, Moultrie H, Meyers T. Six‑month gains in weight, 
height, and CD4 predict subsequent antiretroviral treatment responses in 
HIV‑infected South African children. AIDS. 2011;24(1):139–46.
 10. World Health Organization, United Nations Children’s Fund. WHO child 
growth standards and the identification of severe acute malnutrition in 
infants and children. Geneva: World Health Organization; 2009.
 11. Yotebieng M, Meyers T, Behets F, Davies MA, Keiser O, Ngonyani KZ, et al. 
Age‑specific and sex‑specific weight gain norms to monitor antiretroviral 
therapy in children in low‑income and middle‑income countries. AIDS. 
2015;29(1):101–9.
 12. Desmonde S, Nielan A, Malateste K, Musick B, Patten GE, Duda SN, et al. 
Age‑stratified rates of mortality and key clinical events in youth ages 
0–24 years in the multiregional IeDEA network. In: 9th international 
workshop HIV pediatrics; 20–21 July 2017; Paris, France. 2017.
 13. IeDEA Pediatric Working Group. A survey of paediatric HIV programmatic 
and clinical management practices in Asia and sub‑Saharan Africa—the 
International epidemiologic Databases to Evaluate AIDS (IeDEA). J Int 
AIDS Soc. 2013;16(1):17998.
 14. Desmonde S, Tanser F, Vreeman R, Takassi E, Edmonds A, Lumbiganon 
P, et al. Access to antiretroviral therapy in HIV‑infected children aged 
0–19 years in the International Epidemiology Databases to Evaluate AIDS 
(IeDEA) Global Cohort Consortium, 2004–2015: a prospective cohort 
study. PLoS Med. 2018;15(5):e1002565.
 15. IeDEA Pediatric Working Group. Taking a critical look at the UNAIDS 
global estimates on paediatric and adolescent HIV survival and death. J 
Int AIDS Soc. 2017;20(1):21952.
 16. Sohn AH, Judd A, Mofenson L, Vicari M, Jerene D, Leroy V, et al. Using 
observational data to inform HIV policy change for children and youth. J 
Acquir Immune Defic Syndr. 2018;78(Suppl 1):S22–6.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub‑
lished maps and institutional affiliations.
